Objective:
This study aimed to design a weighted co-expression network and a breast cancer (BC) prognosis evaluation system using a specific whole-genome expression profile combined with epithelial-mesenchymal transition (EMT)-related genes; thus, providing the basis and reference for assessing the prognosis risk of spreading of metastatic breast cancer (MBC) to the bone.
Methods:
Four gene expression datasets of a large number of samples from GEO were downloaded and combined with the dbEMT database to screen out EMT differentially expressed genes (DEGs). Using the GSE20685 dataset as a training set, we designed a weighted co-expression network for EMT DEGs, and the hub genes most relevant to metastasis were selected. We chose eight hub genes to build prognostic assessment models to estimate the 3-, 5-, and 10-year survival rates. We evaluated the models' independent predictive abilities using univariable and multivariable Cox regression analyses. Two GEO datasets related to bone metastases from BC were downloaded and used to perform differential genetic analysis. We used CIBERSORT to distinguish 22 immune cell types based on tumor transcripts.
Results:
Differential expression analysis showed a total of 304 DEGs, which were mainly related to proteoglycans in cancer, and the PI3K/Akt and the TGF-β signaling pathways, as well as mesenchyme development, focal adhesion, and cytokine binding functionally. The 50 hub genes were selected, and a survival-related linear risk assessment model consisting of eight genes (FERMT2, ITGA5, ITGB1, MCAM, CEMIP, HGF, TGFBR1, F2RL2) was constructed. The survival rate of patients in the high-risk group (HRG) was substantially lower than that of the low-risk group (LRG), and the 3-, 5-, and 10-year AUCs were 0.68, 0.687, and 0.672, respectively. In addition, we explored the DEGs of BC bone metastasis, and BMP2, BMPR2, and GREM1 were differentially expressed in both data sets. In GSE20685, memory B cells, resting memory T cell CD4 cells, T regulatory cells (T), γδ T cells, monocytes, M0 macrophages, M2 macrophages, resting dendritic cells (DCs), resting mast cells, and neutrophils exhibited substantially different distribution between HRG and LRG. In GSE45255, there was a considerable difference in abundance of activated NK cells, monocytes, M0 macrophages, M2 macrophages, resting DCs, and neutrophils in HRG and LRG.
Conclusions:
Based on the weighted co-expression network for breast-cancer-metastasis-related DEGs, we screened hub genes to explore a prognostic model and the immune infiltration patterns of MBC. The results of this study provided a factual basis to bioinformatically explore the molecular mechanisms of the spread of MBC to the bone and the possibility of predicting the survival of patients.
Citing Articles
Integrating RNA-seq and scRNA-seq to explore the prognostic features and immune landscape of exosome-related genes in breast cancer metastasis.
Huang G, Yu Y, Su H, Gan H, Chu L
Ann Med. 2025; 57(1):2447917.
PMID: 39847423
PMC: 11758802.
DOI: 10.1080/07853890.2024.2447917.
ITGA5 is associated with prognosis marker and immunosuppression in head and neck squamous cell carcinoma.
Liu J, Wang Y, Chen X, Chen X, Zhang M
Diagn Pathol. 2024; 19(1):134.
PMID: 39375732
PMC: 11457354.
DOI: 10.1186/s13000-024-01559-1.
Integrin β1 in breast cancer: mechanisms of progression and therapy.
Huang Q, Wang J, Ning H, Liu W, Han X
Breast Cancer. 2024; 32(1):43-59.
PMID: 39343856
DOI: 10.1007/s12282-024-01635-w.
Metformin relieves bone cancer pain by reducing TGFβRI-TRPV1 signaling in rats.
Zhou F, Qian H, Wang K, Gu Y, Liu P, Zhang L
Heliyon. 2024; 10(15):e34991.
PMID: 39157315
PMC: 11328085.
DOI: 10.1016/j.heliyon.2024.e34991.
Predictive and Prognostic Relevance of Tumor-Infiltrating Immune Cells: Tailoring Personalized Treatments against Different Cancer Types.
Dakal T, George N, Xu C, Suravajhala P, Kumar A
Cancers (Basel). 2024; 16(9).
PMID: 38730579
PMC: 11082991.
DOI: 10.3390/cancers16091626.
Based on the prognosis model of immunogenes, the prognosis model was constructed to predict the invasion of immune genes and immune cells related to primary liver cancer and its experimental validation.
Yang Y, Bai M, Cheng Y, Feng X, Zhang Y, Zhang Y
Heliyon. 2024; 10(7):e27362.
PMID: 38560168
PMC: 10980948.
DOI: 10.1016/j.heliyon.2024.e27362.
Overexpression of FERM Domain Containing Kindlin 2 (FERMT2) in Fibroblasts Correlates with EMT and Immunosuppression in Gastric Cancer.
Yin S, Liu Y, Li J, Liu J
Int J Genomics. 2024; 2024:4123737.
PMID: 38352691
PMC: 10864055.
DOI: 10.1155/2024/4123737.
The integration of multidisciplinary approaches revealed PTGES3 as a novel drug target for breast cancer treatment.
Yin Q, Ma H, Dong Y, Zhang S, Wang J, Liang J
J Transl Med. 2024; 22(1):84.
PMID: 38245717
PMC: 10800054.
DOI: 10.1186/s12967-024-04899-0.
Unique macrophage phenotypes activated by BMP signaling in breast cancer bone metastases.
Ihle C, Straign D, Canari J, Torkko K, Zolman K, Smith E
JCI Insight. 2024; 9(1).
PMID: 38193534
PMC: 10906463.
DOI: 10.1172/jci.insight.168517.
Predictive and prognostic biomarkers of bone metastasis in breast cancer: current status and future directions.
Wang S, Wu W, Lin X, Zhang K, Wu Q, Luo M
Cell Biosci. 2023; 13(1):224.
PMID: 38041134
PMC: 10693103.
DOI: 10.1186/s13578-023-01171-8.
Robust Identification of Differential Gene Expression Patterns from Multiple Transcriptomics Datasets for Early Diagnosis, Prognosis, and Therapies for Breast Cancer.
Tuly K, Hossen M, Islam M, Kibria M, Alam M, Harun-Or-Roshid M
Medicina (Kaunas). 2023; 59(10).
PMID: 37893423
PMC: 10608013.
DOI: 10.3390/medicina59101705.
Research on the biological mechanism and potential application of CEMIP.
Liu Y, Hu G, Li Y, Kong X, Yang K, Li Z
Front Immunol. 2023; 14:1222425.
PMID: 37662915
PMC: 10471826.
DOI: 10.3389/fimmu.2023.1222425.
Comprehensive analysis of the role of a four-gene signature based on EMT in the prognosis, immunity, and treatment of lung squamous cell carcinoma.
Li F, Wang H, Wang C, Li Y, Song J, Fan K
Aging (Albany NY). 2023; 15(14):6865-6893.
PMID: 37462692
PMC: 10415548.
DOI: 10.18632/aging.204878.
A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q, Zhang P, Zhang X, Feng Y, Li L, Lin H
Front Immunol. 2023; 14:1199040.
PMID: 37313409
PMC: 10258351.
DOI: 10.3389/fimmu.2023.1199040.
CEMIP, a Promising Biomarker That Promotes the Progression and Metastasis of Colorectal and Other Types of Cancer.
Domanegg K, Sleeman J, Schmaus A
Cancers (Basel). 2022; 14(20).
PMID: 36291875
PMC: 9600181.
DOI: 10.3390/cancers14205093.
Newly Released Advances in the Molecular Mechanisms of Osseous Metastasis and Potential Therapeutic Strategies.
Rodriguez-Merchan E, Peleteiro-Pensado M
Arch Bone Jt Surg. 2022; 10(9):741-755.
PMID: 36246026
PMC: 9527427.
DOI: 10.22038/ABJS.2022.57856.2865.
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues.
Penick E, Bateman N, Rojas C, Magana C, Conrads K, Zhou M
Clin Proteomics. 2022; 19(1):35.
PMID: 36195845
PMC: 9531351.
DOI: 10.1186/s12014-022-09372-y.
Identification of hub genes related to CD4 memory T cell infiltration with gene co-expression network predicts prognosis and immunotherapy effect in colon adenocarcinoma.
Tang L, Yu S, Zhang Q, Cai Y, Li W, Yao S
Front Genet. 2022; 13:915282.
PMID: 36105107
PMC: 9465611.
DOI: 10.3389/fgene.2022.915282.
Nomogram Models Based on the Gene Expression in Prediction of Breast Cancer Bone Metastasis.
Fan T, Bei D, Li S
J Healthc Eng. 2022; 2022:8431946.
PMID: 36046013
PMC: 9424032.
DOI: 10.1155/2022/8431946.
FABP6 Expression Correlates with Immune Infiltration and Immunogenicity in Colorectal Cancer Cells.
Lian W, Wang Z, Ma Y, Tong Y, Zhang X, Jin H
J Immunol Res. 2022; 2022:3129765.
PMID: 36033394
PMC: 9403257.
DOI: 10.1155/2022/3129765.